We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+4.77%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$646M
AUM Growth
+$38.6M
Cap. Flow
+$20.8M
Cap. Flow %
3.22%
Top 10 Hldgs %
64.44%
Holding
59
New
19
Increased
16
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$29.4M
2
TSRO
TESARO, Inc.
TSRO
+$21.1M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15.5M
4
ESPR
Esperion Therapeutics
ESPR
+$14.5M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$8.94M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$21.7M
3
SHPG
Shire pic
SHPG
+$20.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$14.9M
5
CORT icon
Corcept Therapeutics
CORT
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 60.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$190M 29.48%
2,000,000
– –
AGN
2
DELISTED
Allergan plc
AGN
$37M 5.73%
222,113
-26,507
-11% -$4.26M
IMMU
3
DELISTED
Immunomedics Inc
IMMU
$31.5M 4.87%
1,329,104
+247,694
+23% +$4.98M
EXEL icon
4
Exelixis
EXEL
$13.8B
$30.6M 4.74%
+1,421,600
New +$29.4M
BMRN icon
5
CALL
BioMarin Pharmaceuticals
BMRN
$11.3B
$28.3M 4.38%
300,000
+192,300
+179% +$16.8M
DOVA
6
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$24.5M 3.8%
820,348
+252,105
+44% +$6.87M
TSRO
7
DELISTED
TESARO, Inc.
TSRO
$19.3M 2.98%
+433,500
New +$21.1M
AZN icon
8
AstraZeneca
AZN
$263B
$18.3M 2.83%
260,140
+18,140
+7% +$1.31M
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
$18.3M 2.83%
404,092
+88,945
+28% +$4.05M
PCRX icon
10
Pacira BioSciences
PCRX
$1.01B
$18.2M 2.81%
566,508
+87,888
+18% +$3.03M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$16.5M 2.55%
+132,623
New +$15.5M
VTRS icon
12
Viatris
VTRS
$19.8B
$15.6M 2.42%
432,009
+171,009
+66% +$6.71M
CLLS
13
Cellectis
CLLS
$282M
$15.5M 2.4%
548,212
+215,458
+65% +$6.42M
INSM icon
14
Insmed
INSM
$23.1B
$15.3M 2.37%
646,863
-271,660
-30% -$6.99M
SGMO
15
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$15.2M 2.35%
1,066,914
+280,538
+36% +$4.66M
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$12.4M 1.92%
79,080
+853
+1% +$134K
ESPR
17
DELISTED
Esperion Therapeutics
ESPR
$11.3M 1.74%
+287,300
New +$14.5M
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
$11.1M 1.72%
828,655
-24,031
-3% -$301K
ABEO icon
19
Abeona Therapeutics
ABEO
$366M
$10M 1.55%
25,072
+10,292
+70% +$4.5M
BOLD
20
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.23M 1.43%
+241,500
New +$8.94M
GYRE icon
21
Gyre Therapeutics
GYRE
$662M
$9.18M 1.42%
104,915
+33,098
+46% +$5.81M
STML
22
DELISTED
Stemline Therapeutics, Inc.
STML
$8.98M 1.39%
559,517
+35,893
+7% +$641K
KYNB
23
Kyntra Bio
KYNB
$29.2M
$8.49M 1.31%
5,423
-613
-10% -$799K
TVRD
24
Tvardi Therapeutics
TVRD
$25.9M
$8.35M 1.29%
12,106
+2,355
+24% +$1.2M
ECYT
25
DELISTED
Endocyte, Inc. Common Stock
ECYT
$8.22M 1.27%
+596,000
New +$7.07M
1
2 3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Nexthera Capital held 59 positions worth $646M, up 6.4% from $607M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Nexthera Capital deployed $20.8M of net new capital in Q2 2018, opening 19 new positions and adding to 16 existing holdings. Its largest new stake was Exelixis: 1,421,600 shares worth $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 63% a quarter earlier.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $14.9M trimmed.

  • Nexthera Capital's largest Q2 2018 buy was Exelixis: 1,421,600 shares worth $30.6M.
  • Nexthera Capital added most to Dova Pharmaceuticals, Inc. Common Stock in Q2 2018, an estimated $6.87M increase.
  • Nexthera Capital's biggest Q2 2018 reduction was Seagen Inc. Common Stock, cutting an estimated $14.9M.
  • Nexthera Capital fully exited BioMarin Pharmaceuticals in Q2 2018, selling an estimated $22.7M.
  • Nexthera Capital's ten largest holdings make up 64% of its $646M portfolio in Q2 2018.
  • Nexthera Capital opened 19 new positions and closed 14 in Q2 2018.
  • Nexthera Capital's portfolio value rose 6.4% quarter-over-quarter to $646M.

Based on Nexthera Capital's 13F filing for Q2 2018, filed 14 Aug 2018.